Program
prabotulinumtoxin A
Also written as “ABP-450”, “PrabotulinumtoxinA-Xvfs” and “DWP450”.
Its studies are mostly in Migraine Disorders · Torticollis, led by 3 companies.
Drug pagePrabotulinumtoxin A: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AEON Biopharmaits history only | 40 open or running | phase 2since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| Daewoong Pharmaceutical | 31 open or running | phase 3since Mar 2, 2020 | Mar 2, 2020 | May 2028phase 3 · NCT07783763 |
| Evolusits history only | 20 open or running | phase 2since Apr 21, 2015 | Apr 21, 2015 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP and ethica Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daewoong Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2020First study: phase 3 study in Benign Masseteric HypertrophyFirst studyNCT04294251 · 180 enrolled · Korea, Republic of
- Apr 3, 2024Phase 3 study in Moderate to Severe Glabellar LinesNCT06354127 · 473 enrolled · China
- Aug 21, 2026Phase 3 study in Glabellar LinesNCT07783763 · 120 planned
Ahead
- May 2028Primary completion: phase 3 study in Glabellar LinesNCT07783763
TargetBeta
“Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme”ChEMBL 37, by rule
Other programs on SNAP25
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| botulinum toxin type A | AbbVie | phase 4 | 286 |
| trenibotulinumtoxinErule | AbbVie | phase 3 | 11 |
Studies
All 3 Daewoong Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07783763Glabellar Lines | 3 | Not yet recruiting | May 2028 | 120 |
| NCT06354127Moderate to Severe Glabellar Lines · China | 3 | Completed | Nov 24, 2020 | 473 |
| NCT04294251Benign Masseteric Hypertrophy · Korea, Republic of | 3 | Completed | Jan 7, 2021 | 180 |
How it is read
Names in the registry
- “ABP-450”, 4 entries
- “PrabotulinumtoxinA-Xvfs”, 2 entries
- “DWP450”, 2 entries
- “DWP450 20 U”, 1 entry
- “DWP-450 (Botulinum purified neurotoxin, Type A)”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 2 studies
- Torticollis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.